1. Home
  2. Labeler Index
  3. Dispensing Solutions, Inc.
  4. 68258-7128
  5. Product Images: Escitalopram

Product Images Escitalopram

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Escitalopram NDC 68258-7128 by Dispensing Solutions, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

NDC 68258-7128-XX - NDC 68258 7128 XX WEST WARD

NDC 68258-7128-XX - NDC 68258 7128 XX WEST WARD

This is a bulk source data of Escitalopram Oxalate tablets, which are scored, round, white, and film-coated. They are dispensed in a tight/light-resistant container and each film-coated tablet contains escitalopram oxalate USP equivalent to 10 mg escitalopram base. The lot number is indicated as XXXXXX, and the pedigree number is 0395563. The tablets are to be taken orally once daily in the morning or evening, as directed by a physician, with or without food, and it is recommended not to use them in combination with MAOIs or alcohol. It could cause drowsiness, and they should be stored at 68°-77° F. The manufacturer is West-Ward Pharmaceutical Corp, located in Eatontown, NJ 07724, and it is distributed by DispenseQuick, Santa Ana, CA 92704.*

Table 1 - escitalopram 1

Table 1 - escitalopram 1

Table 2 - escitalopram 2

Table 2 - escitalopram 2

This is a chart (Table 2) that shows the treatment-emergent adverse reactions observed in patients with major depressive disorder who received Escitalopram Oxalate. The adverse reactions are grouped according to several systems in the body, including the autonomic nervous system, the central and peripheral nervous system, the respiratory system, the gastrointestinal system, and the urogenital system. Some of the observed reactions include sweating, dizziness, constipation, indigestion, decreased appetite, and ejaculation disorders. The denominator used for each adverse reaction varies depending on the specific reaction.*

Table 3 - escitalopram 3

Table 3 - escitalopram 3

This is a table presenting treatment emergent adverse reactions observed in patients with generalized anxiety disorder who were administered Escitalopram oxalate Plash. The table shows the percentage frequency of adverse events with 7% or higher compared to the placebo group. The adverse reactions are divided into different categories, including neurological, gastrointestinal, musculoskeletal, and respiratory disorders, among others. The table presents the data separately for males and females, and it includes the total number of participants used in the analysis.*

Table 4 - escitalopram 4

Table 4 - escitalopram 4

The table lists the incidence of common adverse reactions for patients with major depressive disorder. Various factors such as placebo, 10mg/day, and 20mg/day of Escitalopram were tested against each other. The reactions mentioned in the table include dry mouth, somnolence, sweating, constipation, fatigue, and indigestion.*

Table 5 - escitalopram 5

Table 5 - escitalopram 5

ESC Chem Structure - escitalopram 6

ESC Chem Structure - escitalopram 6

CHO is a chemical compound with the molecular formula CH_FN, - CH.0 and molecular weight of 414.40. Its structural formula is not available.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.